MSCs expressing TLS:CHOP are potential precursors of MRCLS.
(A) Gross (left), H&E (middle), and IHC (right) positivity for TLS:CHOP of MSCs from pTCp53null mice injected subcutaneously into NSG mice. Arrow denotes developing tumor. Original magnification, ×200. (B) NSG mice were xenografted with MSCs from either pTCp53null or p53null mice, divided into cohorts of 10, and treated as in Figure 3 beginning when a tumor nodule was palpable (2–3 mm diameter; assigned as day 1). (C) Histopathology (H&E) of xenografts of MSCs from pTCp53null mice after treatment with RSG and/or ET-743. Original magnification, ×100.